Baldwin Insurance Group, Inc (BWIN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts such as hedge fund buying and analyst upgrades, the lack of strong technical signals, insider selling, and the company's negative net income suggest that it may be better to wait for clearer signs of improvement before investing.
The MACD is positive and contracting, indicating mild bullish momentum. RSI is neutral at 54.767, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing indecision in price direction. Key support is at 19.695, and resistance is at 21.903. Overall, the technical indicators are neutral.

Hedge funds are significantly increasing their buying activity (+684.07% over the last quarter). Analysts from Raymond James and TD Cowen have upgraded the stock, citing valuation and growth potential. The company has a compelling valuation and synergies from its recent CAC Group merger.
Insiders are selling heavily (+577.76% over the last month). The stock is down 23% year-to-date due to AI concerns and near-term headwinds on organic revenue growth. No recent news or significant event-driven catalysts. The company is still reporting negative net income (-$25.86M in Q4 2025).
In Q4 2025, revenue increased by 84.83% YoY to $95.08M, but net income remained negative at -$25.86M, albeit improving by 28.27% YoY. EPS also improved slightly to -0.37 (+12.12% YoY). Gross margin remains at 0%. While revenue growth is strong, the company is still unprofitable.
Recent analyst ratings are mixed but lean positive. UBS lowered its price target to $40 from $44 while maintaining a Buy rating. Raymond James upgraded the stock to Strong Buy with a price target of $30, citing valuation and growth potential. TD Cowen initiated coverage with a Buy rating and a $37 price target. However, JPMorgan and Raymond James previously lowered their price targets due to AI concerns and growth headwinds.